How to Buy Nuvalent Stock
Nuvalent Inc
Nuvalent, Inc. , a clinical stage biopharmaceutical company, develops therapies for patients with cancer.
Nuvalent stock last closed at $97.43, down 1.56% from the previous day, and has increased 27.09% in one year. It has overperformed other stocks in the Biotechnology industry by 0.65 percentage points. Nuvalent stock is currently +75.44% from its 52-week low of $55.54, and -13.79% from its 52-week high of $113.02.
There are currently 78.62M NUVL shares outstanding. The market capitalization of NUVL is $7.66B. In the last 24 hours, 400,000 NUVL shares were traded.
How to Buy Nuvalent Stock
Not sure how to invest in Nuvalent stock? Here's how.
- Figure out where to buy Nuvalent stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you decide where to buy Nuvalent stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Pick your method of payment and add your information.
- Evaluate Nuvalent stock: The Nuvalent ticker symbol is NUVL. Is Nuvalent stock a good investment? Should you buy shares of NUVL? How do NUVL's underlying business fundamentals look? Do top analysts think Nuvalent is a good buy? Why has NUVL's stock price moved recently? (Hint: Our stock research website can help you decide if NUVL is a good stock to buy).
- Place your NUVL buy order: Decide if you will purchase NUVL shares at the current market price or use a limit order to purchase NUVL stock at a given price.
- Keep tabs on your investment in NUVL: Create a watchlist to keep track of your new investment in Nuvalent shares.
Step 1: Figure out where to buy Nuvalent stock
You will need a brokerage account in order to access the NASDAQ market and buy NUVL stock.
Our preferred brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal info so you can invest in NUVL stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've filled out your info on one of the best stock apps, you need to deposit funds:
Watch the tutorial below if you need help depositing money into your new investment account.
Step 4: Evaluate Nuvalent stock
After you have selected the best place to buy Nuvalent stock, it's important to analyze their stock prior to investing, so you truly wrap your head around the risk and upside.
Nuvalent Numbers
Nuvalent Due Diligence Checks
WallStreetZen was designed to help average investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on NUVL's stock page.
How is NUVL stock valued?
You can use many financial metrics, analyses, models, and charts to gauge NUVL's fair value.
Using relative valuations measures:
- NUVL may be overvalued based on its P/B ratio of 6.14x, relative to Biotechnology industry P/B ratio of 4.65x
You can do more valuation analysis on NUVL's stock here.
A look at NUVL Cashflows and Balance Sheet
Positive Health Checks:
- NUVL has cash burn of 275209000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the NUVL balance sheet.
- Total NUVL debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the NUVL balance sheet.
- NUVL has $1.37B in cash and short term investments. This is sufficient to cover its annual cash burn of $275.21M.
- NUVL has a low debt to equity ratio of 0.13.
Is it a good time to buy Nuvalent stock, according to analysts?
Out of 13 sell side analysts who track NUVL, the consensus analyst rating on NUVL is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest NUVL Analyst Forecasts
Bradley Canino, a top 26% analyst from Guggenheim maintains NUVL with a strong buy rating and raises their NUVL price target from $125.00 to $155.00, on Nov 18, 2025.
Guggenheim's Bradley Canino raised their price target on Nuvalent (NASDAQ: NUVL) by 24% from $125 to $155 on 2025/11/18. The analyst maintained their Strong Buy rating on the stock.
Nuvalent reported its Q3 2025 earnings.
Canino told readers they hiked their price target because the positive Neladalkib pivotal data very likely "fully de-risks" Guggenheim's second-to-third-line ALK+ NSCLC odds-of-success estimate and increases its first-line odds to 75%.
Earnings Report
For Q3 2025, Nuvalent reported:
- EPS of $(1.70), which missed the consensus estimate of $(1.35).
- Revenue of $0.00.
Management did not provide financial guidance in its press release.
CEO James Porter, Ph.D., commented: "We are pleased to have recently shared the first report of preliminary clinical data demonstrating the potential for neladalkib to address medical needs for patients with ALK-positive solid tumors beyond NSCLC, and new preclinical data further demonstrating the potential for NVL-330 to offer a differentiated profile for HER2-altered NSCLC.
"With a portfolio anchored by complementary indications in biomarker-driven NSCLC and supported by a robust development and discovery pipeline, we continue to build towards our long-term vision of Nuvalent as a sustainable company capable of designing, developing, and delivering precisely targeted therapies for patients with cancer."
Laura Prendergast, a top 15% analyst from Stifel Nicolaus maintains NUVL with a strong buy rating and raises their NUVL price target from $115.00 to $135.00, on Nov 17, 2025.
Andrew Berens, a bottom 3% analyst from Leerink Partners maintains NUVL with a buy rating and raises their NUVL price target from $140.00 to $149.00, on Nov 17, 2025.
Swayampakula Ramakanth, a top 4% analyst from HC Wainwright & Co. maintains NUVL with a buy rating and raises their NUVL price target from $130.00 to $155.00, on Nov 17, 2025.
John Newman, a bottom 6% analyst from Canaccord Genuity initiates coverage on NUVL with a strong buy rating and announces their NUVL price target of $126.00, on Nov 12, 2025.
You can dive deeper into what analysts are saying on the Nuvalent stock forecast page.
NUVL Technicals
What are NUVL insiders up to?
In the last year, insiders at NUVL have sold more shares than they have bought.
Henry E. Pelish, Chief Scientific Officer of NUVL, was the latest NUVL insider to sell. They sold $78,703.56 worth of NUVL stock on Mar 13, 2026.
Get more info about who owns NUVL stock here.
Can I get consistent income from NUVL stock?
No, Nuvalent doesn't provide an income stream by paying out dividends.
What others are saying about NUVL
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your NUVL buy order
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given dollar amount limit, use a limit order.
Press the Open button and your broker will place the order.
If you need more assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Keep tabs on your investment in NUVL
Now that you own some shares in NUVL, you'll want to keep up with your new stock purchase.
Create a watchlist to track the most important metrics related to your NUVL stock.
NUVL Feed
How to Buy Stock in Nuvalent
To summarize, here are the 6 steps you need to take to buy Nuvalent stock right now:
- Figure out where to buy Nuvalent stock
- Create a brokerage account
- Put funds into your investment account
- Evaluate Nuvalent stock
- Place your NUVL buy order
- Keep tabs on your investment in NUVL
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Nuvalent, create a watchlist on WallStreetZen today.
Other "How To" Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.